日本儿童单价与五价轮状病毒疫苗效果研究
2014年与2015年1月至5月在14家医疗机构对急性胃肠炎儿童开展主动监测,采用检测阴性病例对照设计,487例病例与925例对照纳入分析。所有轮状病毒胃肠炎疫苗有效性为80.0%(95%CI 72.8-85.5%),单价与五价疫苗效果相似;需静脉补液或住院的重症轮状病毒胃肠炎疫苗有效性为97.3%(95%CI 88.8-99.3%)。
要点
- 所有轮状病毒胃肠炎疫苗有效性为80.0%(95%CI 72.8-85.5%)。
- 单价疫苗有效性80.6%(95%CI 70.7-87.1%),五价疫苗80.4%(95%CI 69.1-87.6%)。
- 需静脉补液或住院的重症轮状病毒胃肠炎疫苗有效性为97.3%(95%CI 88.8-99.3%)。
核心结论
- 轮状病毒疫苗对预防轻至重度轮状病毒胃肠炎有效,与疫苗类型、接种后时间或轮状病毒基因型无关。
研究设计与样本
- 2014年与2015年1月至5月,在14家医疗机构对儿童胃肠炎开展主动监测。
- 采用检测阴性病例对照设计,纳入1519名符合条件受试者(≥2月龄至<3岁因急性胃肠炎症状就诊的儿童),最终纳入487例病例和925例对照。
- 通过免疫层析法检测直肠拭子轮状病毒,阳性标本进行基因分型;采用非条件logistic回归分析调整可能的混杂因素。
主要发现
- 病例症状较对照更严重,需要更密集的治疗,包括静脉补液或住院。
- 所有轮状病毒胃肠炎疫苗有效性为80.0%(95%CI 72.8-85.5%),单价疫苗为80.6%(95%CI 70.7-87.1%),五价疫苗为80.4%(95%CI 69.1-87.6%)。
- 两种疫苗有效性均随年龄下降,但接种后2年内对所有轮状病毒胃肠炎的有效性均>70%。
- 疫苗有效性随轮状病毒胃肠炎严重程度增加而升高,需静脉补液或住院的重症轮状病毒胃肠炎疫苗有效性为97.3%(95%CI 88.8-99.3%)。
- 单价疫苗对G1P[8]和G2P[4]的有效性分别为89.8%(95%CI 78.2-95.5%)和78.3%(95%CI 23.6-93.8%);五价疫苗对G1P[8]和G2P[4]的有效性分别为85.8%(95%CI 72.8-92.6%)和88.1%(95%CI 10.1-98.4%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rotavirus (RV) vaccination has been available in Japan since November 2011, but is not yet part of Japan's national immunisation programs. There are insufficient data on vaccine effectiveness (VE) among Japanese children. METHODS: Between the months of January and May in 2014 and 2015, we conducted active surveillance of gastroenteritis among children at 14 medical facilities. Rectal swabs from all patients with diarrhoea or vomiting were tested for RV by immunochromatography, and positive specimens were genotyped. Demographic data and immunisation records were obtained from a questionnaire completed by their parents/guardians or medical records. A test-negative case-control design was used to examine vaccine effectiveness (VE) using unconditional logistic regression analysis adjusted for possible confounding factors. RESULTS: Among the 1519 eligible subjects (children with acute gastroenteritis symptoms aged ≥2 months to <3 y visiting medical facilities) recruited, 487 cases and 925 controls were enrolled. Cases had more severe symptoms than controls, requiring more intensive treatment, including intravenous rehydration or hospitalisation. VE against all rotavirus gastroenteritis (RVGE) was 80.0% (95% confidence interval [CI], 72.8-85.5%), and VEs against RV1 and RV5 were similar, at 80.6% (95%CI, 70.7-87.1%) for RV1 and 80.4% (95% CI, 69.1-87.6%) for RV5. Although VEs of both vaccines decreased with age, VEs against all RVGE were >70% up to 2 years after vaccination. VEs increased with severity of RVGE, and VE against severe RVGE, requiring intravenous rehydration or hospitalisation, was 97.3% (95% CI, 88.8-99.3%). VEs of RV1 and RV5 against G1P[8] and G2P[4] were comparable, at RV1, 89.8% (95% CI, 78.2-95.5%) and 78.3% (95% CI, 23.6-93.8%); and RV5, 85.8% (95% CI, 72.8-92.6%) and 88.1% (95% CI, 10.1-98.4%), respectively. CONCLUSIONS: Rotavirus vaccines were effective in preventing mild to severe RVGE, irrespective of vaccine type, time since vaccination, or RV genotype.
引用
- Araki K, Hara M, Tsugawa T, et al. Effectiveness of monovalent and pentavalent rotavirus vaccines in Japanese children. Vaccine. 2018. PMID: 30037664. doi:10.1016/j.vaccine.2018.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。